This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?
by Zacks Equity Research
During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.
AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) closed at $0.92 in the latest trading session, marking a -0.87% move from the prior day.
AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.
Will AVEO Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in AVEO Pharmaceuticals.
AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) closed at $1 in the latest trading session, marking a -1.96% move from the prior day.
AVEO (AVEO) Up 71.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVEO Pharmaceuticals (AVEO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) closed at $1.10 in the latest trading session, marking a +1.85% move from the prior day.
AVEO Reports Positive Results on Leukemia Drug, Shares Up
by Zacks Equity Research
AVEO Oncology (AVEO) reports positive results from phase Ib study of ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia.
AVEO Pharmaceuticals (AVEO) to File NDA for Fotivda with FDA
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) focuses on the NDA for Fotivda in the United States for the treatment of advanced or metastatic RCC.
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
by Zacks Equity Research
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
Will AVEO Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in AVEO Pharmaceuticals.
AVEO (AVEO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AVEO (AVEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in Q4. However, revenues fall shy of estimates.
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink
by Zacks Equity Research
Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).
AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA
by Zacks Equity Research
AVEO Oncology (AVEO) decides against filing NDA for Fotivda on recommendation of the FDA. The agency remains concerned with the overall survival data.
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
by Zacks Equity Research
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
by Kinjel Shah
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of 16.67% and 262.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About AVEO Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to AVEO stock based on the movements in the options market lately.
AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 6.4% in Session
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) shares rose more than 6% in the last trading session, amid huge volumes.